Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 20/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 20/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 20/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 20/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 20/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 20/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3099633 | 1.00 | PSEN1 (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5220786 | 0.90 | PSEN1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5217189 | 0.90 | PSEN1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3095883 | 0.88 | PSEN1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3092370 | 0.86 | PSEN1 (0.59) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3083700 | 0.82 | PSEN1 (0.55) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3105326 | 0.82 | PSEN1 (0.55) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3090837 | 0.81 | PSEN1 (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3092034 | 0.80 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3099521 | 0.80 | PSEN1 (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795289-B2 | Use of acylaminothiazole derivatives as therapeutic agents | SANOFI-AVENTIS (FR) | 2010-09-14 | — | — | US | disclosed |
| US-20080051436-A1 | Use of Acylaminothiazole Derivatives as Therapeutic Agents | SANOFI-AVENTIS (FR) | 2008-02-28 | — | — | US | disclosed |
| US-7291636-B2 | Acylaminothiazole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-11-06 | — | — | US | disclosed |
| US-20050182104-A1 | Acylaminothiazole derivatives, preparation and therapeutic use thereof | SANOFI-SYNTHELABO (FR) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051436-A1 | Use of Acylaminothiazole Derivatives as Therapeutic Agents | BACE1, BACE2, ATG4A | PSEN1 23/4885PSEN2 42/4885APH1B 6/4885 |
| US-20050182104-A1 | Acylaminothiazole derivatives, preparation and therapeutic use thereof | BACE1, APP, BACE2 | PSEN1 14/4885PSEN2 21/4885APH1B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.